



**CancerCare**  
MANITOBA

---

*Action Cancer Manitoba*

**Annual Statistical Report  
2006**

**Cancer in Manitoba  
Incidence & Mortality**

Epidemiology and Cancer Registry



# CANCER IN MANITOBA

## INCIDENCE AND MORTALITY

### 2006 Annual Statistical Report

EPIDEMIOLOGY AND CANCER REGISTRY

675 McDermot Avenue

Winnipeg, Manitoba Canada

R3E 0V9

Phone: (204) 787-2157

Fax: (204) 786-0628

Email: [registry@cancercare.mb.ca](mailto:registry@cancercare.mb.ca)

<http://www.cancercare.mb.ca>



# Table of Contents

<b>Introduction and staff</b>	1
<b>Place of diagnosis and death, residence at diagnosis and death</b>	3
<b>Incidence and mortality by age distribution</b>	4
<b>Buccal cavity and Pharynx</b>	5
Lip	5
Tongue; Major salivary gland	6
Floor of mouth; Gum and other mouth	7
Nasopharynx; Oropharynx	8
Hypopharynx; Other buccal cavity and pharynx	9
<b>Digestive system</b>	10
Esophagus	10
Stomach	11
Small intestine	12
Colon (excluding rectum)	13
Rectum and rectosigmoid	14
Liver	15
Anus and Gallbladder	16
Pancreas	17
Other digestive system	18
<b>Respiratory</b>	19
Larynx	20
Lung and bronchus	21
Other respiratory system	22
<b>Bones and joints</b>	23
<b>Soft tissue (including heart)</b>	23
<b>Skin</b>	24
Melanoma	25
Other skin and <i>in situ</i>	26
<b>Kaposi sarcoma</b>	26
<b>Breast</b>	27
Breast ( <i>in situ</i> )	27
Breast (invasive)	28

<b>Female genital system</b>	29
Cervix (invasive; <i>in situ</i> )	30
Corpus uteri and Uterus, NOS	31
Ovary and Other female genital system	32
<b>Male genital system</b>	33
Prostate (invasive and <i>in situ</i> )	34
Testis; Penis; Other male genital system	35
<b>Urinary system</b>	36
Bladder ( <i>in situ</i> )	36
Bladder (invasive)	37
Kidney and renal pelvis	38
Ureter; Other urinary system	39
<b>Eye</b>	40
<b>Brain and Other nervous system</b>	40
Brain (invasive); Brain (uncertain and unspecified)	41
Brain and nervous system (benign); Other nervous system	42
<b>Endocrine</b>	43
Thyroid	44
Other endocrine (excluding thyroid)	45
<b>Lymphoma</b>	46
Hodgkin disease	46
Non-Hodgkin lymphoma	47
Multiple Myeloma	48
<b>Leukemia</b>	48
Acute lymphocytic leukemia; Chronic lymphocytic leukemia	49
Acute myeloid leukemia; Chronic myeloid leukemia	50
Other leukemia	51
<b>Other, ill-defined and unknown</b>	51
<b>Neoplasms – uncertain and unspecified (excluding brain)</b>	52
<b>Other in situ (excluding skin, breast, cervix, bladder, prostate)</b>	52
<b>Appendix 1: Incidence by site 2006</b>	53
<b>Appendix 2: Mortality by site 2006</b>	55
<b>Appendix 3: Sites with more than 50 cases (by stage – % and frequency)</b>	57
<b>Appendix 4: ICD–O–3 codes</b>	60





## 2006 ANNUAL STATISTICAL REPORT

### THE MANITOBA CANCER REGISTRY

CancerCare Manitoba is legally mandated under the Public Health Act of Manitoba to collect, classify and maintain accurate comprehensive information on all cancer cases for the province of Manitoba. The Manitoba Cancer Registry is a population-based central cancer registry housed in the Department of Epidemiology and Cancer Registry.

Information sources include:

- Cytology and Pathology Departments in the Province of Manitoba
- Admission/Separation data from the provincial hospital abstracting system
- Vital Statistics deceased information from the provincial Vital Statistics Department
- Letters and “Report of Malignant Neoplasm Forms” from physicians and other health care providers
- Hospital health records
- Correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in their jurisdictions

#### The Cancer Registry Data is utilized for:

- Annual Statistical Reports
- Canadian Cancer Registry (CCR), North American Association of Central Cancer Registries (NAACCR) and the International Association of Cancer Registries (IACR).
- Education
- Health care planning and monitoring
- Surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- Patient care
- Quality assurance

#### Requests for Information

- We respect and protect the right to privacy of the patient and ensure the appropriate use of confidential health information.
- Requests for information for study and research purposes are processed through the Resource Impact Committee and relevant Ethics Boards for approval.
- The Provincial Personal Health Information Act (PHIA) and the Federal Personal Information Protection and Electronic Documents Act (PIPEDA) are complied with at all times.
- Disease related data for diagnostic clarification, treatment planning and previous cancer history can be provided by our Certified Cancer Registrars to assist the physician(s), pathologist(s) and other health care providers directly involved in the care of the patient.
- Statistical information for all published annual report data is available upon request.

#### In 2006, the Cancer Registry staff participated in and/or performed the following:

46	New studies	15	Quality Assurance reviews and edits
25	On-going studies	2	Manitoba Health duplicate match reviews
45	Statistical requests (phone calls/fax requests)	72	Cancer Registry Monthly Edits (six each month)
635	Provision of disease related data for diagnostic clarification and treatment planning including Estrogen and Progesterone report assay results	1	Inter-provincial exchange of information
		12	Death Clearance



The Manitoba Cancer Registry continues to be the Estrogen Progesterone (ER/PR) report assay registry for the Province of Manitoba.

**ANNUAL REPORT GUIDE:**

**INCIDENCE DATA:** Cancer cases diagnosed in the 2006 calendar year. Incidence is also provided by stage of disease at diagnosis.

**MORTALITY DATA:** Manitobans who died of cancer in the 2006 calendar year but not necessarily diagnosed in that year. This information has been provided to us from the Vital Statistics Department, Province of Manitoba. The totals in the summary on page 3 include all cancer deaths occurring in the Province.

**POPULATION DATA:** Data is based on the Statistics Canada population–estimates for Manitoba.

**RATES:** Rates are calculated by dividing the number of cases (incidence and mortality) identified by the number of individuals in that specific category (age/sex/region) multiplied by 100,000.

**CANCER INCIDENCE AND MORTALITY:** Tables of incidence and mortality are categorized in this report according to the International Classification of Diseases for Oncology Third edition (ICD–O–3<sup>rd</sup> ed.).

**NOTE:** All statistics in the body of the annual report include Manitoba residents only.

**EPIDEMIOLOGY and CANCER REGISTRY 2006/2007**

**Cancer Registry Staff:**

**Manager:** Gail Noonan, HRT

**Cancer Registrars:**

Elena Avila, HIT  
Douglas Buffie, HIT  
Jennifer Cadger, HIT  
Angela Deneka, HIT  
Sheila Fukumura, HIT  
Terri–Lee Handel, HIT  
Coreen Hildebrand, HRT, CTR (Sr. Quality Control Technician)  
Jo–Anne Janzen, HRT, CTR (Sr. Cancer Registrar)  
Shannon Kornelsen, HIT  
Loriann Love, HRT  
Grace Pontanares, HIT  
Melissa Scott, HIT  
Kim Shore, HRT  
Kyla Webber, HIT

**Clerical Support:**

Judy Perry (Senior Clerical)  
Sharon Lawrence  
Cherry Pacheco

**Administrative Assistant:**

Karen Carson–Walton

**Epidemiology Staff:**

**Manager:** Donna Turner, PhD

**Epidemiologists:**

Alain Demers, PhD  
Jane Griffith, PhD  
Erich Kliewer, PhD

**Programmer Analysts:**

Wendy Fonseca–Holt, BSc, BCScH  
Humaira Khair, MSc  
Huimin Lu, MSc  
Grace Musto, BSc  
Lin Xue, MSc

**Health Outcomes Analysts:**

Katherine Fradette, BA  
Kimi Guilbert, MSc  
Zoann Nugent, PhD

**Project Manager:**

Cheryl Clague

**Study Managers:**

Carly Leggett  
Caitlin Mills  
Deepak Pruthi

**PLACE OF DIAGNOSIS**

	<b>Male</b>	<b>Female</b>	<b>Total</b>
Health Sciences Centre	1018	781	1799
St. Boniface General Hospital	444	607	1051
Other Hospitals in Winnipeg	891	731	1622
Other Hospitals in Manitoba	864	1408	2272
Hospitals Outside Manitoba	66	102	168
Doctors and Clinics in Winnipeg	942	783	1725
Doctors and Clinics in Manitoba	216	187	403
<b>Total</b>	<b>4441</b>	<b>4599</b>	<b>9040</b>

**PLACE OF DEATH**

	<b>Female</b>	<b>Male</b>	<b>Total</b>
Hospitals - Winnipeg	734	720	1454
Hospitals - Outside Winnipeg	400	480	880
Nursing Homes	43	24	67
Other - Winnipeg	75	92	167
Other - Outside Winnipeg	51	80	131
UNKNOWN	1	0	1
<b>Total</b>	<b>1304</b>	<b>1396</b>	<b>2700</b>

**RESIDENCE AT DIAGNOSIS**

	<b>Male</b>	<b>Female</b>	<b>Total</b>
Winnipeg	2391	2566	4957
Manitoba-Outside Winnipeg	1863	1872	3735
Non-Manitoba Residence	187	161	348
<b>Total</b>	<b>4441</b>	<b>4599</b>	<b>9040</b>

**RESIDENCE AT DEATH**

	<b>Male</b>	<b>Female</b>	<b>Total</b>
Greater Winnipeg	761	794	1555
Manitoba - Outside Greater Winnipeg	624	503	1127
Residence Not Stated	11	7	18
<b>Total</b>	<b>1396</b>	<b>1304</b>	<b>2700</b>

**Age Distribution at Diagnosis for 2006  
(ALL SITES/INVASIVE & *IN SITU*)**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-04	13	35.62	15	43.30	28	39.36
05-09	5	12.87	1	2.72	6	7.94
10-14	6	13.90	8	19.33	14	16.56
15-19	8	18.21	22	52.33	30	34.89
20-24	14	34.11	53	131.93	67	82.49
25-29	17	44.62	86	225.57	103	135.12
30-34	29	75.94	85	223.13	114	149.45
35-39	50	127.62	119	304.00	169	215.77
40-44	82	180.07	202	441.66	284	311.15
45-49	168	360.37	260	567.71	428	463.12
50-54	285	687.71	344	829.28	629	758.53
55-59	380	1055.88	379	1035.49	759	1045.6
60-64	519	1936.13	419	1535.47	938	1734.02
65-69	551	2709.35	436	1994.88	987	2339.25
70-74	635	3681.37	426	2198.82	1061	2897.09
75-79	618	4419.02	533	2911.45	1151	3564.35
80+	874	5016.65	1050	3227.10	1924	3851.16
<b>Total</b>	<b>4254</b>	<b>728.01</b>	<b>4438</b>	<b>740.50</b>	<b>8692</b>	<b>734.33</b>

**Age Distribution at Death for 2006  
(ALL SITES/INVASIVE & *IN SITU*)**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-04	0	0.00	0	0.00	0	0.00
05-09	1	2.57	0	0.00	1	1.32
10-14	1	2.32	0	0.00	1	1.18
15-19	1	2.28	2	4.76	3	3.49
20-24	5	12.18	1	2.49	6	7.39
25-29	0	0.00	5	13.11	5	6.56
30-34	7	18.33	3	7.88	10	13.11
35-39	10	25.52	9	22.99	19	24.26
40-44	20	43.92	22	48.1	42	46.02
45-49	45	96.53	46	100.44	91	98.47
50-54	67	161.67	65	156.69	132	159.18
55-59	93	258.41	83	226.77	176	242.46
60-64	127	473.77	110	403.11	237	438.13
65-69	156	767.07	133	608.53	289	684.95
70-74	186	1078.32	152	784.56	338	922.92
75-79	225	1608.87	168	917.68	393	1217.02
80+	441	2531.28	498	1530.57	939	1879.54
<b>Total</b>	<b>1385</b>	<b>237.02</b>	<b>1297</b>	<b>216.41</b>	<b>2682</b>	<b>226.58</b>

**BUCCAL CAVITY AND PHARYNX (C00:C14)**

**INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	2	2.59	1	1.29	3	1.94
40-49	4	4.34	3	3.28	7	3.81
50-59	27	34.87	7	8.96	34	21.86
60-69	29	61.51	15	30.52	44	45.70
70-79	28	89.65	19	50.42	47	68.20
80+	18	103.32	11	33.81	29	58.05
<b>Total</b>	<b>109</b>	<b>18.65</b>	<b>57</b>	<b>9.51</b>	<b>166</b>	<b>14.02</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.17	0	0.00	2	1.09
50-59	1	1.29	2	2.56	3	1.93
60-69	6	12.73	4	8.14	10	10.39
70-79	10	32.02	2	5.31	12	17.41
80+	5	28.70	4	12.29	9	18.01
<b>Total</b>	<b>24</b>	<b>4.11</b>	<b>12</b>	<b>2.00</b>	<b>36</b>	<b>3.04</b>

**LIP**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	4	5.17	1	1.28	5	3.22
60-69	7	14.85	1	2.03	8	8.31
70-79	14	44.82	3	7.96	17	24.67
80+	8	45.92	7	21.51	15	30.02
<b>Total</b>	<b>33</b>	<b>5.65</b>	<b>12</b>	<b>2.00</b>	<b>45</b>	<b>3.80</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.20	0	0.00	1	1.45
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.17</b>	<b>2</b>	<b>0.17</b>

## TONGUE

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	2	2.59	0	0.00	2	1.29
40-49	1	1.09	1	1.09	2	1.09
50-59	7	9.04	2	2.56	9	5.79
60-69	4	8.48	7	14.24	11	11.42
70-79	1	3.20	7	18.58	8	11.61
80+	2	11.48	1	3.07	3	6.00
<b>Total</b>	<b>18</b>	<b>3.08</b>	<b>18</b>	<b>3.00</b>	<b>36</b>	<b>3.04</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.17	0	0.00	2	1.09
50-59	0	0.00	1	1.28	1	0.64
60-69	1	2.12	1	2.03	2	2.08
70-79	2	6.40	1	2.65	3	4.35
80+	4	22.96	0	0.00	4	8.01
<b>Total</b>	<b>9</b>	<b>1.54</b>	<b>3</b>	<b>0.50</b>	<b>12</b>	<b>1.01</b>

## MAJOR SALIVARY GLAND

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	1	1.29	0	0.00	1	0.64
60-69	2	4.24	2	4.07	4	4.15
70-79	0	0.00	0	0.00	0	0.00
80+	3	17.22	2	6.15	5	10.01
<b>Total</b>	<b>6</b>	<b>1.03</b>	<b>6</b>	<b>1.00</b>	<b>12</b>	<b>1.01</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.12	1	2.03	2	2.08
70-79	1	3.20	1	2.65	2	2.90
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>3</b>	<b>0.50</b>	<b>5</b>	<b>0.42</b>

## FLOOR OF MOUTH

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	4	8.48	0	0.00	4	4.15
70-79	0	0.00	2	5.31	2	2.90
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>4</b>	<b>0.68</b>	<b>2</b>	<b>0.33</b>	<b>6</b>	<b>0.51</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.08</b>

## GUM AND OTHER MOUTH

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	4	5.17	2	2.56	6	3.86
60-69	5	10.61	3	6.10	8	8.31
70-79	2	6.40	2	5.31	4	5.80
80+	2	11.48	1	3.07	3	6.00
<b>Total</b>	<b>13</b>	<b>2.22</b>	<b>9</b>	<b>1.50</b>	<b>22</b>	<b>1.86</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.29	0	0.00	1	0.64
60-69	1	2.12	0	0.00	1	1.04
70-79	1	3.20	0	0.00	1	1.45
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>0</b>	<b>0.00</b>	<b>3</b>	<b>0.25</b>

## NASOPHARYNX

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	1	1.29	1	0.65
40-49	0	0.00	0	0.00	0	0.00
50-59	3	3.87	0	0.00	3	1.93
60-69	2	4.24	1	2.03	3	3.12
70-79	0	0.00	1	2.65	1	1.45
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>3</b>	<b>0.50</b>	<b>8</b>	<b>0.68</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.12	1	2.03	2	2.08
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.17</b>	<b>2</b>	<b>0.17</b>

## OROPHARYNX

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	2	4.24	0	0.00	2	2.08
70-79	1	3.20	0	0.00	1	1.45
80+	1	5.74	0	0.00	1	2.00
<b>Total</b>	<b>4</b>	<b>0.68</b>	<b>0</b>	<b>0.00</b>	<b>4</b>	<b>0.34</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	2	4.24	1	2.03	3	3.12
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>1</b>	<b>0.17</b>	<b>3</b>	<b>0.25</b>

## HYPOPHARYNX

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	4	5.17	0	0.00	4	2.57
60-69	1	2.12	0	0.00	1	1.04
70-79	4	12.81	3	7.96	7	10.16
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>9</b>	<b>1.54</b>	<b>3</b>	<b>0.50</b>	<b>12</b>	<b>1.01</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.20	0	0.00	1	1.45
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.08</b>

## OTHER BUCCAL CAVITY AND PHARYNX

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	3	3.26	0	0.00	3	1.63
50-59	4	5.17	2	2.56	6	3.86
60-69	2	4.24	1	2.03	3	3.12
70-79	6	19.21	1	2.65	7	10.16
80+	2	11.48	0	0.00	2	4.00
<b>Total</b>	<b>17</b>	<b>2.91</b>	<b>4</b>	<b>0.67</b>	<b>21</b>	<b>1.77</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.28	1	0.64
60-69	0	0.00	0	0.00	0	0.00
70-79	4	12.81	0	0.00	4	5.80
80+	1	5.74	1	3.07	2	4.00
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>2</b>	<b>0.33</b>	<b>7</b>	<b>0.59</b>



## DIGESTIVE SYSTEM (C15:C26)

### INCIDENCE - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	6	2.57	6	1.26
30-39	11	14.22	10	12.95	21	13.58
40-49	40	43.40	26	28.40	66	35.93
50-59	111	143.35	76	97.33	187	120.25
60-69	167	354.24	86	175.00	253	262.76
70-79	197	630.72	169	448.50	366	531.09
80+	153	878.20	193	593.17	346	692.57
<b>Total</b>	<b>679</b>	<b>116.20</b>	<b>566</b>	<b>94.44</b>	<b>1245</b>	<b>105.18</b>

### MORTALITY - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	11	14.22	2	2.59	13	8.41
40-49	19	20.62	12	13.11	31	16.88
50-59	57	73.61	31	39.70	88	56.59
60-69	72	152.73	38	77.32	110	114.24
70-79	112	358.58	80	212.31	192	278.60
80+	115	660.08	135	414.91	250	500.41
<b>Total</b>	<b>386</b>	<b>66.06</b>	<b>299</b>	<b>49.89</b>	<b>685</b>	<b>57.87</b>

## ESOPHAGUS

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	2	2.59	1	1.29	3	1.94
40-49	1	1.09	0	0.00	1	0.54
50-59	8	10.33	0	0.00	8	5.14
60-69	13	27.58	1	2.03	14	14.54
70-79	8	25.61	4	10.62	12	17.41
80+	2	11.48	2	6.15	4	8.01
<b>Total</b>	<b>34</b>	<b>5.82</b>	<b>8</b>	<b>1.33</b>	<b>42</b>	<b>3.55</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	4	5.17	0	0.00	4	2.59
40-49	4	4.34	0	0.00	4	2.18
50-59	7	9.04	2	2.56	9	5.79
60-69	13	27.58	1	2.03	14	14.54
70-79	9	28.81	6	15.92	15	21.77
80+	9	51.66	6	18.44	15	30.02
<b>Total</b>	<b>46</b>	<b>7.87</b>	<b>15</b>	<b>2.50</b>	<b>61</b>	<b>5.15</b>


## STOMACH

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	6	6.51	2	2.18	8	4.36
50-59	12	15.50	6	7.68	18	11.57
60-69	11	23.33	1	2.03	12	12.46
70-79	16	51.23	10	26.54	26	37.73
80+	20	114.80	14	43.03	34	68.06
<b>Total</b>	<b>66</b>	<b>11.29</b>	<b>33</b>	<b>5.51</b>	<b>99</b>	<b>8.36</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	3	3.88	0	0.00	3	1.94
40-49	2	2.17	1	1.09	3	1.63
50-59	8	10.33	4	5.12	12	7.72
60-69	7	14.85	3	6.10	10	10.39
70-79	18	57.63	10	26.54	28	40.63
80+	13	74.62	9	27.66	22	44.04
<b>Total</b>	<b>51</b>	<b>8.73</b>	<b>27</b>	<b>4.51</b>	<b>78</b>	<b>6.59</b>



\*See Appendix 3 for frequency of incidence for each site

**SMALL INTESTINE**

**INCIDENCE**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.17	0	0.00	2	1.09
50-59	4	5.17	2	2.56	6	3.86
60-69	6	12.73	0	0.00	6	6.23
70-79	5	16.01	1	2.65	6	8.71
80+	3	17.22	3	9.22	6	12.01
<b>Total</b>	<b>20</b>	<b>3.42</b>	<b>6</b>	<b>1.00</b>	<b>26</b>	<b>2.20</b>

**MORTALITY**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.29	0	0.00	1	0.64
60-69	0	0.00	0	0.00	0	0.00
70-79	3	9.60	0	0.00	3	4.35
80+	1	5.74	2	6.15	3	6.00
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>2</b>	<b>0.33</b>	<b>7</b>	<b>0.59</b>

**COLON (EXCLUDING RECTUM)**


**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	2	0.86	2	0.42
30-39	4	5.17	5	6.47	9	5.82
40-49	11	11.94	7	7.65	18	9.80
50-59	35	45.20	32	40.98	67	43.08
60-69	56	118.79	35	71.22	91	94.51
70-79	90	288.15	88	233.54	178	258.29
80+	62	355.87	94	288.90	156	312.26
<b>Total</b>	<b>258</b>	<b>44.15</b>	<b>263</b>	<b>43.88</b>	<b>521</b>	<b>44.02</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	4	4.37	5	2.72
50-59	16	20.66	12	15.37	28	18.00
60-69	23	48.79	7	14.24	30	31.16
70-79	39	124.86	26	69.00	65	94.32
80+	40	229.59	56	172.11	96	192.16
<b>Total</b>	<b>119</b>	<b>20.37</b>	<b>105</b>	<b>17.52</b>	<b>224</b>	<b>18.92</b>

**Incidence of Colon Cancer (excluding Rectum)  
by Stage\***



\*See Appendix 3 for frequency of incidence for each site

## RECTUM AND RECTOSIGMOID


### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	1	1.29	2	1.29
40-49	10	10.85	5	5.46	15	8.17
50-59	27	34.87	18	23.05	45	28.94
60-69	54	114.55	24	48.84	78	81.01
70-79	34	108.86	29	76.96	63	91.42
80+	32	183.68	33	101.42	65	130.11
<b>Total</b>	<b>158</b>	<b>27.04</b>	<b>110</b>	<b>18.35</b>	<b>268</b>	<b>22.64</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	1	1.29	2	2.59	3	1.94
40-49	1	1.09	1	1.09	2	1.09
50-59	3	3.87	5	6.40	8	5.14
60-69	5	10.61	5	10.17	10	10.39
70-79	9	28.81	6	15.92	15	21.77
80+	21	120.54	19	58.40	40	80.07
<b>Total</b>	<b>40</b>	<b>6.85</b>	<b>39</b>	<b>6.51</b>	<b>79</b>	<b>6.67</b>

**Incidence of Rectal and Rectosigmoid Cancer  
by Stage\***



\*See Appendix 3 for frequency of incidence for each site


## LIVER

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	1	1.29	0	0.00	1	0.65
40-49	1	1.09	2	2.18	3	1.63
50-59	10	12.91	2	2.56	12	7.72
60-69	6	12.73	3	6.10	9	9.35
70-79	10	32.02	2	5.31	12	17.41
80+	8	45.92	8	24.59	16	32.03
<b>Total</b>	<b>36</b>	<b>6.16</b>	<b>18</b>	<b>3.00</b>	<b>54</b>	<b>4.56</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	1	1.09	2	2.18	3	1.63
50-59	6	7.75	0	0.00	6	3.86
60-69	6	12.73	2	4.07	8	8.31
70-79	11	35.22	3	7.96	14	20.31
80+	7	40.18	7	21.51	14	28.02
<b>Total</b>	<b>32</b>	<b>5.48</b>	<b>14</b>	<b>2.34</b>	<b>46</b>	<b>3.89</b>



\*See Appendix 3 for frequency of incidence for each site

## ANUS

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	3	3.88	3	1.94
40-49	0	0.00	3	3.28	3	1.63
50-59	1	1.29	4	5.12	5	3.22
60-69	0	0.00	1	2.03	1	1.04
70-79	0	0.00	1	2.65	1	1.45
80+	2	11.48	3	9.22	5	10.01
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>15</b>	<b>2.50</b>	<b>18</b>	<b>1.52</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.29	1	1.28	2	1.29
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	2	6.15	2	4.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>3</b>	<b>0.50</b>	<b>4</b>	<b>0.34</b>

## GALLBLADDER

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	3	3.28	3	1.63
50-59	0	0.00	1	1.28	1	0.64
60-69	2	4.24	3	6.10	5	5.19
70-79	1	3.20	6	15.92	7	10.16
80+	0	0.00	3	9.22	3	6.00
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>16</b>	<b>2.67</b>	<b>19</b>	<b>1.61</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	3	6.10	3	3.12
70-79	1	3.20	4	10.62	5	7.26
80+	1	5.74	1	3.07	2	4.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>9</b>	<b>1.50</b>	<b>11</b>	<b>0.93</b>


**PANCREAS**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	5	5.43	2	2.18	7	3.81
50-59	10	12.91	8	10.25	18	11.57
60-69	15	31.82	10	20.35	25	25.96
70-79	23	73.64	22	58.38	45	65.30
80+	18	103.32	26	79.91	44	88.07
<b>Total</b>	<b>72</b>	<b>12.32</b>	<b>68</b>	<b>11.35</b>	<b>140</b>	<b>11.83</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	7	7.60	3	3.28	10	5.44
50-59	12	15.50	4	5.12	16	10.29
60-69	12	25.45	12	24.42	24	24.93
70-79	12	38.42	22	58.38	34	49.34
80+	16	91.84	27	82.98	43	86.07
<b>Total</b>	<b>60</b>	<b>10.27</b>	<b>68</b>	<b>11.35</b>	<b>128</b>	<b>10.81</b>



\*See Appendix 3 for frequency of incidence for each site



OTHER DIGESTIVE SYSTEM

**INCIDENCE**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	3	1.29	3	0.63
30-39	1	1.29	0	0.00	1	0.65
40-49	4	4.34	2	2.18	6	3.27
50-59	4	5.17	3	3.84	7	4.50
60-69	4	8.48	8	16.28	12	12.46
70-79	10	32.02	6	15.92	16	23.22
80+	6	34.44	7	21.51	13	26.02
<b>Total</b>	<b>29</b>	<b>4.96</b>	<b>29</b>	<b>4.84</b>	<b>58</b>	<b>4.90</b>

**MORTALITY**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	3	3.26	0	0.00	3	1.63
50-59	3	3.87	3	3.84	6	3.86
60-69	6	12.73	5	10.17	11	11.42
70-79	10	32.02	3	7.96	13	18.86
80+	7	40.18	6	18.44	13	26.02
<b>Total</b>	<b>30</b>	<b>5.13</b>	<b>17</b>	<b>2.84</b>	<b>47</b>	<b>3.97</b>

**RESPIRATORY SYSTEM (C30:39)**

**INCIDENCE - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	1	0.41	1	0.43	2	0.42
30-39	2	2.59	3	3.88	5	3.23
40-49	6	6.51	16	17.48	22	11.98
50-59	68	87.82	71	90.93	139	89.38
60-69	138	292.73	107	217.73	245	254.45
70-79	152	486.65	108	286.62	260	377.28
80+	93	533.81	91	279.68	184	368.30
<b>Total</b>	<b>460</b>	<b>78.72</b>	<b>397</b>	<b>66.24</b>	<b>857</b>	<b>72.40</b>

**MORTALITY - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	15	16.28	12	13.11	27	14.70
50-59	42	54.24	43	55.07	85	54.66
60-69	96	203.64	89	181.10	185	192.13
70-79	118	377.79	88	233.54	206	298.92
80+	95	545.29	86	264.31	181	362.30
<b>Total</b>	<b>367</b>	<b>62.81</b>	<b>318</b>	<b>53.06</b>	<b>685</b>	<b>57.87</b>

## LARYNX

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	6	7.75	0	0.00	6	3.86
60-69	10	21.21	2	4.07	12	12.46
70-79	7	22.41	3	7.96	10	14.51
80+	3	17.22	2	6.15	5	10.01
Total	26	4.45	7	1.17	33	2.79

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	4	8.48	0	0.00	4	4.15
70-79	4	12.81	1	2.65	5	7.26
80+	4	22.96	0	0.00	4	8.01
Total	12	2.05	1	0.17	13	1.10

## LUNG AND BRONCHUS


### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	2	2.59	3	3.88	5	3.23
40-49	6	6.51	15	16.39	21	11.43
50-59	60	77.49	71	90.93	131	84.24
60-69	125	265.15	105	213.66	230	238.87
70-79	139	445.03	104	276.00	243	352.61
80+	85	487.89	88	270.46	173	346.28
<b>Total</b>	<b>418</b>	<b>71.53</b>	<b>387</b>	<b>64.57</b>	<b>805</b>	<b>68.01</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	15	16.28	12	13.11	27	14.70
50-59	42	54.24	42	53.79	84	54.01
60-69	92	195.15	89	181.10	181	187.98
70-79	113	361.79	87	230.89	200	290.21
80+	89	510.85	83	255.09	172	344.28
<b>Total</b>	<b>352</b>	<b>60.24</b>	<b>313</b>	<b>52.23</b>	<b>665</b>	<b>56.18</b>

**Incidence of Lung and Bronchus Cancer  
by Stage\***



*"Occult" carcinoma: Malignant cells are present in bronchopulmonary secretions, but no tumour seen radiographically or during bronchoscopy.*

\*See Appendix 3 for frequency of incidence for each site

## OTHER RESPIRATORY SYSTEM

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	2	2.58	0	0.00	2	1.29
60-69	3	6.36	0	0.00	3	3.12
70-79	6	19.21	1	2.65	7	10.16
80+	5	28.70	1	3.07	6	12.01
<b>Total</b>	<b>16</b>	<b>2.74</b>	<b>3</b>	<b>0.50</b>	<b>19</b>	<b>1.61</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.28	1	0.64
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.20	0	0.00	1	1.45
80+	2	11.48	3	9.22	5	10.01
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>4</b>	<b>0.67</b>	<b>7</b>	<b>0.59</b>

## BONES AND JOINTS (C40:41)

### INCIDENCE - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	1	1.29	0	0.00	1	0.65
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.29	0	0.00	1	0.64
60-69	1	2.12	2	4.07	3	3.12
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>4</b>	<b>0.68</b>	<b>3</b>	<b>0.50</b>	<b>7</b>	<b>0.59</b>

### MORTALITY - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	3	6.36	0	0.00	3	3.12
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>4</b>	<b>0.68</b>	<b>1</b>	<b>0.17</b>	<b>5</b>	<b>0.42</b>

## SOFT TISSUE (INCLUDING HEART)

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	3	1.24	5	2.14	8	1.69
30-39	1	1.29	2	2.59	3	1.94
40-49	3	3.26	1	1.09	4	2.18
50-59	1	1.29	1	1.28	2	1.29
60-69	1	2.12	2	4.07	3	3.12
70-79	5	16.01	4	10.62	9	13.06
80+	2	11.48	0	0.00	2	4.00
<b>Total</b>	<b>16</b>	<b>2.74</b>	<b>15</b>	<b>2.50</b>	<b>31</b>	<b>2.62</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	1	0.43	3	0.63
30-39	1	1.29	0	0.00	1	0.65
40-49	1	1.09	0	0.00	1	0.54
50-59	4	5.17	2	2.56	6	3.86
60-69	4	8.48	1	2.03	5	5.19
70-79	6	19.21	0	0.00	6	8.71
80+	6	34.44	1	3.07	7	14.01
<b>Total</b>	<b>24</b>	<b>4.11</b>	<b>5</b>	<b>0.83</b>	<b>29</b>	<b>2.45</b>

**SKIN - MELANOMA & NON-MELANOMA (C44)**

**INCIDENCE - TOTAL (INCLUDES *IN SITU*)**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	10	4.14	14	6.01	24	5.06
30-39	31	40.07	30	38.84	61	39.46
40-49	108	117.19	107	116.90	215	117.04
50-59	194	250.55	160	204.91	354	227.63
60-69	253	536.67	203	413.07	456	473.58
70-79	362	1158.99	255	676.73	617	895.31
80+	298	1710.48	351	1078.77	649	1299.07
<b>Total</b>	<b>1256</b>	<b>214.95</b>	<b>1120</b>	<b>186.88</b>	<b>2376</b>	<b>200.73</b>

**MORTALITY - TOTAL (INCLUDES *IN SITU*)**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	2	2.18	3	1.63
50-59	5	6.46	2	2.56	7	4.50
60-69	5	10.61	1	2.03	6	6.23
70-79	7	22.41	4	10.62	11	15.96
80+	6	34.44	5	15.37	11	22.02
<b>Total</b>	<b>24</b>	<b>4.11</b>	<b>14</b>	<b>2.34</b>	<b>38</b>	<b>3.21</b>


## MELANOMA OF THE SKIN

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	5	2.14	6	1.26
30-39	4	5.17	3	3.88	7	4.53
40-49	13	14.11	6	6.55	19	10.34
50-59	12	15.50	15	19.21	27	17.36
60-69	15	31.82	14	28.49	29	30.12
70-79	16	51.23	12	31.85	28	40.63
80+	16	91.84	13	39.95	29	58.05
<b>Total</b>	<b>77</b>	<b>13.18</b>	<b>68</b>	<b>11.35</b>	<b>145</b>	<b>12.25</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	2	2.18	3	1.63
50-59	5	6.46	2	2.56	7	4.50
60-69	4	8.48	1	2.03	5	5.19
70-79	5	16.01	2	5.31	7	10.16
80+	3	17.22	3	9.22	6	12.01
<b>Total</b>	<b>18</b>	<b>3.08</b>	<b>10</b>	<b>1.67</b>	<b>28</b>	<b>2.37</b>



\*See Appendix 3 for frequency of incidence for each site



**OTHER SKIN AND *IN SITU*<sup>1</sup>**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	9	3.73	9	3.86	18	3.79
30-39	27	34.90	27	34.96	54	34.93
40-49	95	103.09	101	110.34	196	106.70
50-59	182	235.05	145	185.70	327	210.27
60-69	238	504.85	189	384.58	427	443.47
70-79	346	1107.77	243	644.89	589	854.68
80+	282	1618.64	338	1038.82	620	1241.02
<b>Total</b>	<b>1179</b>	<b>201.77</b>	<b>1052</b>	<b>175.53</b>	<b>2231</b>	<b>188.48</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.12	0	0.00	1	1.04
70-79	2	6.40	2	5.31	4	5.80
80+	3	17.22	2	6.15	5	10.01
<b>Total</b>	<b>6</b>	<b>1.03</b>	<b>4</b>	<b>0.67</b>	<b>10</b>	<b>0.84</b>

<sup>1</sup>Includes melanoma *in situ*

**KAPOSI SARCOMA**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.17	0	0.00	2	1.09
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>1</b>	<b>0.17</b>	<b>4</b>	<b>0.34</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.20	0	0.00	1	1.45
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.08</b>

**BREAST – INVASIVE AND *IN SITU* (C500:C509)**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	2	0.86	2	0.42
30-39	0	0.00	33	42.72	33	21.34
40-49	0	0.00	145	158.41	145	78.94
50-59	1	1.29	209	267.66	210	135.04
60-69	2	4.24	225	457.84	227	235.75
70-79	0	0.00	153	406.04	153	222.01
80+	1	5.74	153	470.23	154	308.25
<b>Total</b>	<b>4</b>	<b>0.68</b>	<b>920</b>	<b>153.51</b>	<b>924</b>	<b>78.06</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	5	6.47	5	3.23
40-49	0	0.00	20	21.85	20	10.89
50-59	0	0.00	24	30.74	24	15.43
60-69	1	2.12	36	73.25	37	38.43
70-79	1	3.20	36	95.54	37	53.69
80+	0	0.00	87	267.39	87	174.14
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>209</b>	<b>34.87</b>	<b>211</b>	<b>17.83</b>

**BREAST – *IN SITU***

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	3	3.88	3	1.94
40-49	0	0.00	25	27.31	25	13.61
50-59	0	0.00	30	38.42	30	19.29
60-69	1	2.12	28	56.98	29	30.12
70-79	0	0.00	15	39.81	15	21.77
80+	0	0.00	9	27.66	9	18.01
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>110</b>	<b>18.35</b>	<b>111</b>	<b>9.38</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>


## BREAST – INVASIVE

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00–29	0	0.00	2	0.86	2	0.42
30–39	0	0.00	30	38.84	30	19.40
40–49	0	0.00	120	131.10	120	65.33
50–59	1	1.29	179	229.24	180	115.75
60–69	1	2.12	197	400.86	198	205.64
70–79	0	0.00	138	366.23	138	200.25
80+	1	5.74	144	442.57	145	290.24
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>810</b>	<b>135.15</b>	<b>813</b>	<b>68.69</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00–29	0	0.00	1	0.43	1	0.21
30–39	0	0.00	5	6.47	5	3.23
40–49	0	0.00	20	21.85	20	10.89
50–59	0	0.00	24	30.74	24	15.43
60–69	1	2.12	36	73.25	37	38.43
70–79	1	3.20	36	95.54	37	53.69
80+	0	0.00	87	267.39	87	174.14
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>209</b>	<b>34.87</b>	<b>211</b>	<b>17.83</b>



\*See Appendix 3 for frequency of incidence for each site

## FEMALE GENITAL SYSTEM (C51:C58)<sup>1</sup>


### INCIDENCE - TOTAL

Age	Female	Rate
00-29	101	43.33
30-39	79	102.28
40-49	74	80.84
50-59	82	105.02
60-69	89	181.10
70-79	57	151.27
80+	47	144.45
<b>Total</b>	<b>529</b>	<b>88.27</b>

<sup>1</sup>Includes cervix *in situ*

### MORTALITY - TOTAL

Age	Female	Rate
00-29	0	0.00
30-39	1	1.29
40-49	4	4.37
50-59	19	24.33
60-69	25	50.87
70-79	25	66.35
80+	34	104.50
<b>Total</b>	<b>108</b>	<b>18.02</b>




### CERVIX - INVASIVE

#### INCIDENCE

Age	Female	Rate
00-29	5	2.14
30-39	3	3.88
40-49	19	20.76
50-59	9	11.53
60-69	3	6.10
70-79	4	10.62
80+	4	12.29
<b>Total</b>	<b>47</b>	<b>7.84</b>

#### MORTALITY

Age	Female	Rate
00-29	0	0.00
30-39	1	1.29
40-49	1	1.09
50-59	0	0.00
60-69	1	2.03
70-79	2	5.31
80+	4	12.29
<b>Total</b>	<b>9</b>	<b>1.50</b>



\*See Appendix 3 for frequency of incidence for each site

### CERVIX - IN SITU

#### INCIDENCE

Age	Female	Rate
00-29	90	38.61
30-39	65	84.15
40-49	27	29.50
50-59	9	11.53
60-69	9	18.31
70-79	2	5.31
80+	0	0.00
<b>Total</b>	<b>202</b>	<b>33.70</b>

#### MORTALITY

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>


## CORPUS UTERI

### INCIDENCE

Age	Female	Rate
00-29	1	0.43
30-39	5	6.47
40-49	14	15.29
50-59	41	52.51
60-69	51	103.78
70-79	28	74.31
80+	22	67.62
<b>Total</b>	<b>162</b>	<b>27.03</b>

### MORTALITY

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	2	2.56
60-69	1	2.03
70-79	4	10.62
80+	5	15.37
<b>Total</b>	<b>12</b>	<b>2.00</b>



\*See Appendix 3 for frequency of incidence for each site

## UTERUS, NOS

### INCIDENCE

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>

### MORTALITY

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	3	6.10
70-79	2	5.31
80+	2	6.15
<b>Total</b>	<b>7</b>	<b>1.17</b>


OVARY

**INCIDENCE**

Age	Female	Rate
00-29	4	1.72
30-39	5	6.47
40-49	12	13.11
50-59	18	23.05
60-69	18	36.63
70-79	20	53.08
80+	18	55.32
<b>Total</b>	<b>95</b>	<b>15.85</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	2	2.18
50-59	17	21.77
60-69	18	36.63
70-79	13	34.50
80+	20	61.47
<b>Total</b>	<b>70</b>	<b>11.68</b>



\*See Appendix 3 for frequency of incidence for each site

OTHER FEMALE GENITAL SYSTEM

**INCIDENCE**

Age	Female	Rate
00-29	1	0.43
30-39	1	1.29
40-49	2	2.18
50-59	5	6.40
60-69	8	16.28
70-79	3	7.96
80+	3	9.22
<b>Total</b>	<b>23</b>	<b>3.84</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	1	1.09
50-59	0	0.00
60-69	2	4.07
70-79	4	10.62
80+	3	9.22
<b>Total</b>	<b>10</b>	<b>1.67</b>

## MALE GENITAL SYSTEM (C60:C63)<sup>1</sup>


### INCIDENCE - TOTAL

Age	Male	Rate
00-29	9	3.73
30-39	10	12.93
40-49	17	18.45
50-59	111	143.35
60-69	242	513.33
70-79	230	736.38
80+	111	637.13
Total	730	124.93

<sup>1</sup>Including prostate *in situ*

### MORTALITY - TOTAL

Age	Male	Rate
00-29	1	0.41
30-39	0	0.00
40-49	1	1.09
50-59	6	7.75
60-69	12	25.45
70-79	40	128.07
80+	83	476.41
Total	143	24.47






**PROSTATE – INVASIVE**

**INCIDENCE**

Age	Male	Rate
00–29	0	0.00
30–39	0	0.00
40–49	11	11.94
50–59	103	133.02
60–69	232	492.12
70–79	223	713.97
80+	104	596.95
<b>Total</b>	<b>673</b>	<b>115.17</b>

**MORTALITY**

Age	Male	Rate
00–29	0	0.00
30–39	0	0.00
40–49	0	0.00
50–59	6	7.75
60–69	12	25.45
70–79	39	124.86
80+	83	476.41
<b>Total</b>	<b>140</b>	<b>23.96</b>



\*See Appendix 3 for frequency of incidence for each site

**PROSTATE – *IN SITU***

**INCIDENCE**

Age	Male	Rate
00–29	0	0.00
30–39	0	0.00
40–49	0	0.00
50–59	6	7.75
60–69	8	16.97
70–79	4	12.81
80+	3	17.22
<b>Total</b>	<b>21</b>	<b>3.59</b>

**MORTALITY**

Age	Male	Rate
00–29	0	0.00
30–39	0	0.00
40–49	0	0.00
50–59	0	0.00
60–69	0	0.00
70–79	0	0.00
80+	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>

## TESTIS

### INCIDENCE

Age	Male	Rate
00-29	9	3.73
30-39	10	12.93
40-49	6	6.51
50-59	1	1.29
60-69	1	2.12
70-79	2	6.40
80+	2	11.48
Total	31	5.31

### MORTALITY

Age	Male	Rate
00-29	1	0.41
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
Total	1	0.17

## PENIS

### INCIDENCE

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	1	2.12
70-79	1	3.20
80+	2	11.48
Total	4	0.68

### MORTALITY

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	1	1.09
50-59	0	0.00
60-69	0	0.00
70-79	1	3.20
80+	0	0.00
Total	2	0.34

## OTHER MALE GENITAL SYSTEM

### INCIDENCE

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	1	1.29
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
Total	1	0.17

### MORTALITY

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
Total	0	0.00

**URINARY SYSTEM (C64:C68)**

**INCIDENCE - TOTAL (INCLUDING BLADDER *IN SITU*)**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	1	0.43	3	0.63
30-39	4	5.17	3	3.88	7	4.53
40-49	24	26.04	10	10.92	34	18.51
50-59	40	51.66	24	30.74	64	41.15
60-69	90	190.91	23	46.80	113	117.36
70-79	113	361.79	35	92.89	148	214.76
80+	78	447.71	39	119.86	117	234.19
<b>Total</b>	<b>351</b>	<b>60.07</b>	<b>135</b>	<b>22.53</b>	<b>486</b>	<b>41.06</b>

**MORTALITY - TOTAL (INCLUDING BLADDER *IN SITU*)**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	5	5.43	2	2.18	7	3.81
50-59	8	10.33	2	2.56	10	6.43
60-69	20	42.42	5	10.17	25	25.96
70-79	22	70.44	11	29.19	33	47.89
80+	32	183.68	21	64.54	53	106.09
<b>Total</b>	<b>87</b>	<b>14.89</b>	<b>41</b>	<b>6.84</b>	<b>128</b>	<b>10.81</b>

**BLADDER - *IN SITU***

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	4	4.34	1	1.09	5	2.72
50-59	15	19.37	4	5.12	19	12.22
60-69	31	65.76	8	16.28	39	40.50
70-79	31	99.25	10	26.54	41	59.49
80+	24	137.76	2	6.15	26	52.04
<b>Total</b>	<b>106</b>	<b>18.14</b>	<b>25</b>	<b>4.17</b>	<b>131</b>	<b>11.07</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>


## BLADDER - INVASIVE

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	3	3.26	2	2.18	5	2.72
50-59	6	7.75	4	5.12	10	6.43
60-69	20	42.42	5	10.17	25	25.96
70-79	40	128.07	8	21.23	48	69.65
80+	29	166.46	21	64.54	50	100.08
<b>Total</b>	<b>98</b>	<b>16.77</b>	<b>40</b>	<b>6.67</b>	<b>138</b>	<b>11.66</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	3	3.87	0	0.00	3	1.93
60-69	7	14.85	2	4.07	9	9.35
70-79	13	41.62	4	10.62	17	24.67
80+	19	109.06	8	24.59	27	54.04
<b>Total</b>	<b>42</b>	<b>7.19</b>	<b>14</b>	<b>2.34</b>	<b>56</b>	<b>4.73</b>



\*See Appendix 3 for frequency of incidence for each site

## KIDNEY AND RENAL PELVIS


### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	1	0.43	3	0.63
30-39	3	3.88	3	3.88	6	3.88
40-49	16	17.36	7	7.65	23	12.52
50-59	18	23.25	15	19.21	33	21.22
60-69	34	72.12	8	16.28	42	43.62
70-79	38	121.66	15	39.81	53	76.91
80+	24	137.76	13	39.95	37	74.06
<b>Total</b>	<b>135</b>	<b>23.10</b>	<b>62</b>	<b>10.34</b>	<b>197</b>	<b>16.64</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	5	5.43	2	2.18	7	3.81
50-59	4	5.17	2	2.56	6	3.86
60-69	13	27.58	3	6.10	16	16.62
70-79	9	28.81	7	18.58	16	23.22
80+	13	74.62	11	33.81	24	48.04
<b>Total</b>	<b>44</b>	<b>7.53</b>	<b>25</b>	<b>4.17</b>	<b>69</b>	<b>5.83</b>

**Incidence of Kidney and Renal Cell Cancer  
by Stage\***



\*See Appendix 3 for frequency of incidence for each site

## URETER

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	0	0.00	1	0.54
50-59	1	1.29	1	1.28	2	1.29
60-69	3	6.36	1	2.03	4	4.15
70-79	1	3.20	2	5.31	3	4.35
80+	0	0.00	2	6.15	2	4.00
<b>Total</b>	<b>6</b>	<b>1.03</b>	<b>6</b>	<b>1.00</b>	<b>12</b>	<b>1.01</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.08</b>

## OTHER URINARY SYSTEM

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	2	4.24	1	2.03	3	3.12
70-79	3	9.60	0	0.00	3	4.35
80+	1	5.74	1	3.07	2	4.00
<b>Total</b>	<b>6</b>	<b>1.03</b>	<b>2</b>	<b>0.33</b>	<b>8</b>	<b>0.68</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.29	0	0.00	1	0.64
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.17</b>	<b>2</b>	<b>0.17</b>

EYE (C69)

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	2	2.18	2	1.09
50-59	1	1.29	0	0.00	1	0.64
60-69	1	2.12	1	2.03	2	2.08
70-79	1	3.20	1	2.65	2	2.90
80+	0	0.00	1	3.07	1	2.00
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>6</b>	<b>1.00</b>	<b>9</b>	<b>0.76</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	1	2.03	1	1.04
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.08</b>

BRAIN AND OTHER NERVOUS SYSTEM (C70:C72)

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	11	4.55	8	3.43	19	4.00
30-39	4	5.17	5	6.47	9	5.82
40-49	8	8.68	11	12.02	19	10.34
50-59	10	12.91	16	20.49	26	16.72
60-69	13	27.58	16	32.56	29	30.12
70-79	13	41.62	26	69.00	39	56.59
80+	9	51.66	17	52.25	26	52.04
<b>Total</b>	<b>68</b>	<b>11.64</b>	<b>99</b>	<b>16.52</b>	<b>167</b>	<b>14.11</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	3	1.24	0	0.00	3	0.63
30-39	1	1.29	1	1.29	2	1.29
40-49	7	7.60	5	5.46	12	6.53
50-59	10	12.91	3	3.84	13	8.36
60-69	9	19.09	2	4.07	11	11.42
70-79	9	28.81	7	18.58	16	23.22
80+	5	28.70	7	21.51	12	24.02
<b>Total</b>	<b>44</b>	<b>7.53</b>	<b>25</b>	<b>4.17</b>	<b>69</b>	<b>5.83</b>

## BRAIN – INVASIVE

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00–29	9	3.73	6	2.57	15	3.16
30–39	3	3.88	3	3.88	6	3.88
40–49	2	2.17	6	6.55	8	4.36
50–59	6	7.75	6	7.68	12	7.72
60–69	8	16.97	5	10.17	13	13.50
70–79	3	9.60	4	10.62	7	10.16
80+	4	22.96	1	3.07	5	10.01
<b>Total</b>	<b>35</b>	<b>5.99</b>	<b>31</b>	<b>5.17</b>	<b>66</b>	<b>5.58</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00–29	2	0.83	0	0.00	2	0.42
30–39	1	1.29	1	1.29	2	1.29
40–49	6	6.51	5	5.46	11	5.99
50–59	8	10.33	2	2.56	10	6.43
60–69	8	16.97	1	2.03	9	9.35
70–79	6	19.21	6	15.92	12	17.41
80+	1	5.74	3	9.22	4	8.01
<b>Total</b>	<b>32</b>	<b>5.48</b>	<b>18</b>	<b>3.00</b>	<b>50</b>	<b>4.22</b>

\*In keeping with international coding conventions, all invasive brain tumours are considered unstageable

## BRAIN – UNCERTAIN AND UNSPECIFIED

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00–29	0	0.00	1	0.43	1	0.21
30–39	1	1.29	0	0.00	1	0.65
40–49	2	2.17	0	0.00	2	1.09
50–59	2	2.58	0	0.00	2	1.29
60–69	1	2.12	0	0.00	1	1.04
70–79	3	9.60	0	0.00	3	4.35
80+	0	0.00	3	9.22	3	6.00
<b>Total</b>	<b>9</b>	<b>1.54</b>	<b>4</b>	<b>0.67</b>	<b>13</b>	<b>1.10</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00–29	1	0.41	0	0.00	1	0.21
30–39	0	0.00	0	0.00	0	0.00
40–49	1	1.09	0	0.00	1	0.54
50–59	2	2.58	1	1.28	3	1.93
60–69	1	2.12	1	2.03	2	2.08
70–79	3	9.60	1	2.65	4	5.80
80+	4	22.96	2	6.15	6	12.01
<b>Total</b>	<b>12</b>	<b>2.05</b>	<b>5</b>	<b>0.83</b>	<b>17</b>	<b>1.44</b>



## BRAIN AND NERVOUS SYSTEM - BENIGN

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	1	0.43	3	0.63
30-39	0	0.00	2	2.59	2	1.29
40-49	4	4.34	5	5.46	9	4.90
50-59	2	2.58	10	12.81	12	7.72
60-69	4	8.48	11	22.38	15	15.58
70-79	7	22.41	22	58.38	29	42.08
80+	5	28.70	13	39.95	18	36.03
Total	24	4.11	64	10.68	88	7.43

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.07	1	2.00
Total	0	0.00	1	0.17	1	0.08

## OTHER NERVOUS SYSTEM

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
Total	0	0.00	0	0.00	0	0.00

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.07	1	2.00
Total	0	0.00	1	0.17	1	0.08

**ENDOCRINE SYSTEM (C73:C75)**

**INCIDENCE - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	2	0.83	11	4.72	13	2.74
30-39	4	5.17	12	15.54	16	10.35
40-49	3	3.26	16	17.48	19	10.34
50-59	7	9.04	6	7.68	13	8.36
60-69	6	12.73	7	14.24	13	13.50
70-79	5	16.01	5	13.27	10	14.51
80+	1	5.74	7	21.51	8	16.01
<b>Total</b>	<b>28</b>	<b>4.79</b>	<b>64</b>	<b>10.68</b>	<b>92</b>	<b>7.77</b>

**MORTALITY - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.28	1	0.64
60-69	1	2.12	0	0.00	1	1.04
70-79	1	3.20	1	2.65	2	2.90
80+	0	0.00	3	9.22	3	6.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>6</b>	<b>1.00</b>	<b>8</b>	<b>0.68</b>


## THYROID

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	10	4.29	12	2.53
30-39	4	5.17	12	15.54	16	10.35
40-49	3	3.26	16	17.48	19	10.34
50-59	5	6.46	6	7.68	11	7.07
60-69	6	12.73	7	14.24	13	13.50
70-79	2	6.40	4	10.62	6	8.71
80+	0	0.00	7	21.51	7	14.01
<b>Total</b>	<b>22</b>	<b>3.76</b>	<b>62</b>	<b>10.34</b>	<b>84</b>	<b>7.10</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.28	1	0.64
60-69	1	2.12	0	0.00	1	1.04
70-79	1	3.20	1	2.65	2	2.90
80+	0	0.00	3	9.22	3	6.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>5</b>	<b>0.83</b>	<b>7</b>	<b>0.59</b>



\*See Appendix 3 for frequency of incidence for each site

OTHER ENDOCRINE (EXCLUDING THYROID)

INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	2	2.58	0	0.00	2	1.29
60-69	0	0.00	0	0.00	0	0.00
70-79	3	9.60	1	2.65	4	5.80
80+	1	5.74	0	0.00	1	2.00
Total	6	1.03	2	0.33	8	0.68

MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
Total	0	0.00	1	0.17	1	0.08

## LYMPHOMA (C77)

### INCIDENCE - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	8	3.31	9	3.86	17	3.58
30-39	4	5.17	9	11.65	13	8.41
40-49	11	11.94	15	16.39	26	14.15
50-59	28	36.16	16	20.49	44	28.29
60-69	31	65.76	23	46.80	54	56.08
70-79	31	99.25	38	100.85	69	100.12
80+	22	126.28	28	86.06	50	100.08
Total	135	23.10	138	23.03	273	23.06

### MORTALITY - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	2	2.59	1	1.29	3	1.94
40-49	3	3.26	5	5.46	8	4.36
50-59	11	14.21	2	2.56	13	8.36
60-69	16	33.94	9	18.31	25	25.96
70-79	22	70.44	14	37.15	36	52.24
80+	19	109.06	30	92.20	49	98.08
Total	73	12.49	62	10.34	135	11.41

## HODGKIN DISEASE

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	3	1.24	8	3.43	11	2.32
30-39	3	3.88	2	2.59	5	3.23
40-49	1	1.09	1	1.09	2	1.09
50-59	3	3.87	1	1.28	4	2.57
60-69	1	2.12	2	4.07	3	3.12
70-79	1	3.20	4	10.62	5	7.26
80+	0	0.00	1	3.07	1	2.00
Total	12	2.05	19	3.17	31	2.62

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	1	1.29	0	0.00	1	0.65
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	2	4.24	0	0.00	2	2.08
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
Total	3	0.51	1	0.17	4	0.34


## NON-HODGKIN LYMPHOMA

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	5	2.07	1	0.43	6	1.26
30-39	1	1.29	7	9.06	8	5.17
40-49	10	10.85	14	15.29	24	13.07
50-59	25	32.29	15	19.21	40	25.72
60-69	30	63.64	21	42.73	51	52.97
70-79	30	96.05	34	90.23	64	92.87
80+	22	126.28	27	82.98	49	98.08
<b>Total</b>	<b>123</b>	<b>21.05</b>	<b>119</b>	<b>19.86</b>	<b>242</b>	<b>20.45</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	1	1.29	2	1.29
40-49	3	3.26	5	5.46	8	4.36
50-59	11	14.21	2	2.56	13	8.36
60-69	14	29.70	9	18.31	23	23.89
70-79	22	70.44	14	37.15	36	52.24
80+	19	109.06	30	92.20	49	98.08
<b>Total</b>	<b>70</b>	<b>11.98</b>	<b>61</b>	<b>10.18</b>	<b>131</b>	<b>11.07</b>



\*See Appendix 3 for frequency of incidence for each site

## MULTIPLE MYELOMA

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.29	0	0.00	1	0.65
40-49	0	0.00	2	2.18	2	1.09
50-59	6	7.75	3	3.84	9	5.79
60-69	4	8.48	7	14.24	11	11.42
70-79	9	28.81	7	18.58	16	23.22
80+	7	40.18	13	39.95	20	40.03
<b>Total</b>	<b>27</b>	<b>4.62</b>	<b>32</b>	<b>5.34</b>	<b>59</b>	<b>4.98</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	0	0.00	1	0.54
50-59	2	2.58	4	5.12	6	3.86
60-69	8	16.97	4	8.14	12	12.46
70-79	9	28.81	7	18.58	16	23.22
80+	4	22.96	11	33.81	15	30.02
<b>Total</b>	<b>24</b>	<b>4.11</b>	<b>26</b>	<b>4.34</b>	<b>50</b>	<b>4.22</b>

## LEUKEMIA (C42)

### INCIDENCE - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	11	4.55	8	3.43	19	4.00
30-39	1	1.29	3	3.88	4	2.59
40-49	5	5.43	6	6.55	11	5.99
50-59	17	21.96	9	11.53	26	16.72
60-69	19	40.30	14	28.49	33	34.27
70-79	24	76.84	14	37.15	38	55.14
80+	14	80.36	18	55.32	32	64.05
<b>Total</b>	<b>91</b>	<b>15.57</b>	<b>72</b>	<b>12.01</b>	<b>163</b>	<b>13.77</b>

### MORTALITY - TOTAL

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	1	1.29	0	0.00	1	0.65
40-49	5	5.43	1	1.09	6	3.27
50-59	6	7.75	3	3.84	9	5.79
60-69	6	12.73	11	22.38	17	17.66
70-79	19	60.83	11	29.19	30	43.53
80+	13	74.62	14	43.03	27	54.04
<b>Total</b>	<b>51</b>	<b>8.73</b>	<b>40</b>	<b>6.67</b>	<b>91</b>	<b>7.69</b>

## ACUTE LYMPHOCYTIC LEUKEMIA

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	7	2.90	5	2.14	12	2.53
30-39	0	0.00	1	1.29	1	0.65
40-49	1	1.09	0	0.00	1	0.54
50-59	1	1.29	0	0.00	1	0.64
60-69	1	2.12	1	2.03	2	2.08
70-79	2	6.40	0	0.00	2	2.90
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>12</b>	<b>2.05</b>	<b>7</b>	<b>1.17</b>	<b>19</b>	<b>1.61</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	1	1.29	0	0.00	1	0.65
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	1	2.03	1	1.04
70-79	1	3.20	0	0.00	1	1.45
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>3</b>	<b>0.51</b>	<b>1</b>	<b>0.17</b>	<b>4</b>	<b>0.34</b>

## CHRONIC LYMPHOCYTIC LEUKEMIA

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	1	1.29	1	0.65
40-49	0	0.00	0	0.00	0	0.00
50-59	7	9.04	4	5.12	11	7.07
60-69	9	19.09	8	16.28	17	17.66
70-79	11	35.22	8	21.23	19	27.57
80+	9	51.66	10	30.73	19	38.03
<b>Total</b>	<b>36</b>	<b>6.16</b>	<b>31</b>	<b>5.17</b>	<b>67</b>	<b>5.66</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	2	2.58	1	1.28	3	1.93
60-69	0	0.00	1	2.03	1	1.04
70-79	3	9.60	1	2.65	4	5.80
80+	6	34.44	2	6.15	8	16.01
<b>Total</b>	<b>11</b>	<b>1.88</b>	<b>5</b>	<b>0.83</b>	<b>16</b>	<b>1.35</b>



## ACUTE MYELOID LEUKEMIA

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	2	0.86	4	0.84
30-39	0	0.00	1	1.29	1	0.65
40-49	1	1.09	3	3.28	4	2.18
50-59	3	3.87	1	1.28	4	2.57
60-69	7	14.85	4	8.14	11	11.42
70-79	6	19.21	5	13.27	11	15.96
80+	1	5.74	5	15.37	6	12.01
<b>Total</b>	<b>20</b>	<b>3.42</b>	<b>21</b>	<b>3.50</b>	<b>41</b>	<b>3.46</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	3	3.26	1	1.09	4	2.18
50-59	3	3.87	1	1.28	4	2.57
60-69	4	8.48	5	10.17	9	9.35
70-79	7	22.41	5	13.27	12	17.41
80+	1	5.74	4	12.29	5	10.01
<b>Total</b>	<b>18</b>	<b>3.08</b>	<b>16</b>	<b>2.67</b>	<b>34</b>	<b>2.87</b>

## CHRONIC MYELOID LEUKEMIA

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	1	0.43	3	0.63
30-39	1	1.29	0	0.00	1	0.65
40-49	1	1.09	2	2.18	3	1.63
50-59	3	3.87	4	5.12	7	4.50
60-69	2	4.24	0	0.00	2	2.08
70-79	3	9.60	1	2.65	4	5.80
80+	2	11.48	1	3.07	3	6.00
<b>Total</b>	<b>14</b>	<b>2.40</b>	<b>9</b>	<b>1.50</b>	<b>23</b>	<b>1.94</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	0	0.00	1	0.54
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.20	0	0.00	1	1.45
80+	0	0.00	3	9.22	3	6.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>3</b>	<b>0.50</b>	<b>5</b>	<b>0.42</b>

## OTHER LEUKEMIAS

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.17	1	1.09	3	1.63
50-59	3	3.87	0	0.00	3	1.93
60-69	0	0.00	1	2.03	1	1.04
70-79	2	6.40	0	0.00	2	2.90
80+	2	11.48	2	6.15	4	8.01
<b>Total</b>	<b>9</b>	<b>1.54</b>	<b>4</b>	<b>0.67</b>	<b>13</b>	<b>1.10</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.09	0	0.00	1	0.54
50-59	1	1.29	1	1.28	2	1.29
60-69	2	4.24	4	8.14	6	6.23
70-79	7	22.41	5	13.27	12	17.41
80+	6	34.44	5	15.37	11	22.02
<b>Total</b>	<b>17</b>	<b>2.91</b>	<b>15</b>	<b>2.50</b>	<b>32</b>	<b>2.70</b>

## OTHER, ILL-DEFINED AND UNKNOWN (C76:C80)

### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	0	0.00	4	5.18	4	2.59
40-49	7	7.60	6	6.55	13	7.08
50-59	11	14.21	15	19.21	26	16.72
60-69	30	63.64	19	38.66	49	50.89
70-79	31	99.25	29	76.96	60	87.06
80+	37	212.38	40	122.94	77	154.13
<b>Total</b>	<b>117</b>	<b>20.02</b>	<b>114</b>	<b>19.02</b>	<b>231</b>	<b>19.52</b>

### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	2	0.86	2	0.42
30-39	0	0.00	2	2.59	2	1.29
40-49	5	5.43	5	5.46	10	5.44
50-59	8	10.33	10	12.81	18	11.57
60-69	20	42.42	16	32.56	36	37.39
70-79	29	92.85	32	84.92	61	88.51
80+	43	246.81	45	138.30	88	176.14
<b>Total</b>	<b>105</b>	<b>17.97</b>	<b>112</b>	<b>18.69</b>	<b>217</b>	<b>18.33</b>

**NEOPLASMS - UNCERTAIN AND UNSPECIFIED  
(EXCLUDING BRAIN)  
INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	13	5.58	15	3.16
30-39	3	3.88	8	10.36	11	7.11
40-49	8	8.68	16	17.48	24	13.07
50-59	24	31.00	20	25.61	44	28.29
60-69	34	72.12	10	20.35	44	45.70
70-79	40	128.07	27	71.65	67	97.22
80+	24	137.76	34	104.50	58	116.10
<b>Total</b>	<b>135</b>	<b>23.10</b>	<b>128</b>	<b>21.36</b>	<b>263</b>	<b>22.22</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	4	8.48	1	2.03	5	5.19
70-79	5	16.01	2	5.31	7	10.16
80+	15	86.10	15	46.10	30	60.05
<b>Total</b>	<b>24</b>	<b>4.11</b>	<b>18</b>	<b>3.00</b>	<b>42</b>	<b>3.55</b>

**OTHER *IN SITU*  
(EXCLUDING SKIN, BREAST, CERVIX, BLADDER, PROSTATE)  
INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	2	0.86	2	0.42
30-39	0	0.00	2	2.59	2	1.29
40-49	4	4.34	6	6.55	10	5.44
50-59	7	9.04	8	10.25	15	9.65
60-69	9	19.09	6	12.21	15	15.58
70-79	12	38.42	12	31.85	24	34.83
80+	6	34.44	6	18.44	12	24.02
<b>Total</b>	<b>38</b>	<b>6.50</b>	<b>42</b>	<b>7.01</b>	<b>80</b>	<b>6.76</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>

APPENDIX 1

INCIDENCE BY SITE, 2006

Site	Male	Female	Total
Lip	33	12	45
Tongue	18	18	36
Major salivary gland	6	6	12
Floor of mouth	4	2	6
Gum and other mouth	13	9	22
Nasopharynx	5	3	8
Oropharynx	4	0	4
Hypopharynx	9	3	12
Other buccal cavity and pharynx	17	4	21
Esophagus	34	8	42
Stomach	66	33	99
Small intestine	20	6	26
Colon (excluding rectum)	258	263	521
Rectum and rectosigmoid	158	110	268
Anus	3	15	18
Liver	36	18	54
Gallbladder	3	16	19
Pancreas	72	68	140
Other digestive system	29	29	58
Larynx	26	7	33
Lung and bronchus	418	387	805
Other respiratory system	16	3	19
Bones and joints	4	3	7
Soft tissue (including heart)	16	15	31
Melanoma of the skin	77	68	145
Kaposi sarcoma	3	1	4
Breast (invasive)	3	810	813
Cervix uteri	0	47	47
Corpus uteri	0	162	162
Uterus, NOS	0	0	0
Ovary	0	95	95
Other female genital system	0	23	23
Prostate (invasive)	673	0	673
Testis	31	0	31
Penis	4	0	4
Other male genital system	1	0	1

Site	Male	Female	Total
Bladder (invasive)	98	40	138
Kidney and renal pelvis	135	62	197
Ureter	6	6	12
Other urinary system	6	2	8
Eye	3	6	9
Brain	35	31	66
Other nervous system	0	0	0
Thyroid	22	62	84
Other endocrine	6	2	8
Hodgkin disease	12	19	31
Non-Hodgkin lymphoma	123	119	242
Multiple myeloma	27	32	59
Acute lymphocytic leukemia	12	7	19
Chronic lymphocytic leukemia	36	31	67
Acute myeloid leukemia	20	21	41
Chronic myeloid leukemia	14	9	23
Other leukemias	9	4	13
Other, ill defined and unknown	117	114	231
<b>TOTAL: INVASIVE CANCERS</b>	<b>2741</b>	<b>2811</b>	<b>5552</b>
Other skin and <i>in situ</i> (including melanoma <i>in situ</i> )	1179	1052	2231
Breast <i>in situ</i>	1	110	111
Cervix <i>in situ</i>	0	202	202
Prostate <i>in situ</i>	21	0	21
Bladder <i>in situ</i>	106	25	131
Other <i>in situ</i> (excluding skin, breast, cervix, prostate, bladder)	38	42	80
<b>TOTAL: IN SITU CANCERS</b>	<b>1345</b>	<b>1431</b>	<b>2776</b>
Brain – uncertain and unspecified	9	4	13
Neoplasms – uncertain and unspecified (excluding brain)	135	128	263
Brain and nervous system benign	24	64	88
<b>TOTAL: OTHER CANCERS</b>	<b>168</b>	<b>196</b>	<b>364</b>
<b>TOTAL: ALL CANCERS/ALL SITES</b>	<b>4254</b>	<b>4438</b>	<b>8692</b>

APPENDIX 2

MORTALITY BY SITE, 2006

Site	Male	Female	Total
Lip	1	1	2
Tongue	9	3	12
Major salivary gland	2	3	5
Floor of mouth	0	1	1
Gum and other mouth	3	0	3
Nasopharynx	1	1	2
Oropharynx	2	1	3
Hypopharynx	1	0	1
Other buccal cavity and pharynx	5	2	7
Esophagus	46	15	61
Stomach	51	27	78
Small intestine	5	2	7
Colon (excluding rectum)	119	105	224
Rectum and rectosigmoid	40	39	79
Anus	1	3	4
Liver	32	14	46
Gallbladder	2	9	11
Pancreas	60	68	128
Other digestive system	30	17	47
Larynx	12	1	13
Lung and bronchus	352	313	665
Other respiratory system	3	4	7
Bones and joints	4	1	5
Soft tissue (including heart)	24	5	29
Melanoma of the skin	18	10	28
Kaposi sarcoma	1	0	1
Breast (invasive)	2	209	211
Cervix uteri	0	9	9
Corpus uteri	0	12	12
Uterus, NOS	0	7	7
Ovary	0	70	70
Other female genital system	0	10	10
Prostate (invasive)	140	0	140
Testis	1	0	1
Penis	2	0	2
Other male genital system	0	0	0

Site	Male	Female	Total
Bladder (invasive)	42	14	56
Kidney and renal pelvis	44	25	69
Ureter	0	1	1
Other urinary system	1	1	2
Eye	0	1	1
Brain	32	18	50
Other nervous system	0	1	1
Thyroid	2	5	7
Other endocrine	0	1	1
Hodgkin disease	3	1	4
Non-Hodgkin lymphoma	70	61	131
Multiple myeloma	24	26	50
Acute lymphocytic leukemia	3	1	4
Chronic lymphocytic leukemia	11	5	16
Acute myeloid leukemia	18	16	34
Chronic myeloid leukemia	2	3	5
Other leukemia	17	15	32
Other, ill-defined and unknown	105	112	217
<b>TOTAL: INVASIVE CANCERS</b>	<b>1343</b>	<b>1269</b>	<b>2612</b>
Other skin and <i>in situ</i> (including melanoma <i>in situ</i> )	6	4	10
Breast <i>in situ</i>	0	0	0
Cervix <i>in situ</i>	0	0	0
Bladder <i>in situ</i>	0	0	0
Prostate <i>in situ</i>	0	0	0
Other <i>in situ</i> (excluding skin, breast, cervix, prostate, bladder)	0	0	0
<b>TOTAL: <i>IN SITU</i> CANCERS</b>	<b>6</b>	<b>4</b>	<b>10</b>
Brain – uncertain and unspecified	12	5	17
Neoplasms – uncertain and unspecified (excluding brain)	24	18	42
Brain and nervous system benign	0	1	1
<b>TOTAL: OTHER CANCERS</b>	<b>36</b>	<b>24</b>	<b>60</b>
<b>TOTAL: ALL CANCERS</b>	<b>1385</b>	<b>1297</b>	<b>2682</b>

**APPENDIX 3**

**STAGING ON SITES WITH MORE THAN 45 CASES\***

<b>Site</b>	<b>Stage</b>	<b>Percent</b>	<b>Frequency</b>
Stomach	Stage I	15.15	15
	Stage II	8.08	8
	Stage III	13.13	13
	Stage IV	34.34	34
	Unknown/NA	29.29	29
			99
Colon (excluding rectum)	Stage I	18.62	97
	Stage II	30.13	157
	Stage III	24.76	129
	Stage IV	20.92	109
	Unknown/NA	5.57	29
			521
Rectum and rectosigmoid	Stage I	19.78	53
	Stage II	26.49	71
	Stage III	27.99	75
	Stage IV	17.16	46
	Unknown/NA	8.58	23
			268
Pancreas	Stage I	12.14	17
	Stage II	15.71	22
	Stage III	5.71	8
	Stage IV	52.86	74
	Unknown/NA	13.57	19
			140
Liver	Stage I	29.63	16
	Stage II	18.52	10
	Stage III	20.37	11
	Stage IV	14.81	8
	Unknown/NA	16.67	9
			54
Lung and bronchus	Occult carcinoma	1.74	14
	Stage I	18.76	151
	Stage II	6.46	52
	Stage III	23.23	187
	Stage IV	43.85	353
	Unknown/NA	5.96	48
			805



Site	Stage	Percent	Frequency
Melanoma of the skin	Stage I	48.97	71
	Stage II	23.45	34
	Stage III	9.66	14
	Stage IV	4.14	6
	Unknown/NA	13.79	20
			145
Breast	Stage I	40.34	328
	Stage II	37.52	305
	Stage III	12.55	102
	Stage IV	6.15	50
	Unknown/NA	3.44	28
			813
Cervix uteri	Stage I	36.17	17
	Stage II	27.66	13
	Stage III	25.53	12
	Stage IV	6.38	3
	Unknown/NA	4.26	2
			47
Corpus uteri	Stage I	67.90	110
	Stage II	12.96	21
	Stage III	9.26	15
	Stage IV	4.94	8
	Unknown/NA	4.94	8
			162
Ovary	Stage I	25.26	24
	Stage II	9.47	9
	Stage III	24.21	23
	Stage IV	29.47	28
	Unknown/NA	11.58	11
			95
Prostate	Stage I	0.00	0
	Stage II	74.89	504
	Stage III	9.96	67
	Stage IV	11.14	75
	Unknown/NA	4.01	27
			673

Site	Stage	Percent	Frequency
Bladder	Stage I	42.03	58
	Stage II	18.12	25
	Stage III	14.49	20
	Stage IV	15.94	22
	Unknown/NA	9.42	13
			138
Kidney and renal pelvis	Stage I	40.61	80
	Stage II	5.58	11
	Stage III	18.27	36
	Stage IV	31.47	62
	Unknown/NA	4.06	8
			197
Thyroid	Stage I	69.05	58
	Stage II	7.14	6
	Stage III	9.52	8
	Stage IV	7.14	6
	Unknown/NA	7.14	6
			84
Non-Hodgkin lymphoma	Stage I	28.93	70
	Stage II	14.05	34
	Stage III	12.40	30
	Stage IV	42.56	103
	Unknown/NA	2.07	5
			242

\*In keeping with international coding conventions, all invasive brain tumours are considered unstageable.

**APPENDIX 4:**

**INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY**  
**3rd EDITION**

<b>Primary Site</b>	<b>Site/ Cell type</b>
<b>Buccal cavity and pharynx</b>	C00:C14
Lip	C000:C009
Tongue	C019:C029
Major salivary gland	C079:C089
Floor of mouth	C040:C049
Gum and other mouth	C030:C039, C050:C059, C060:C069
Nasopharynx	C110:C119
Oropharynx	C100:C109
Hypopharynx	C129, C130:C139
Other buccal cavity and pharynx	C090:C099, C140, C142:C148
<b>Digestive system</b>	C15:C26
Esophagus	C150:C159
Stomach	C160:C169
Small intestine	C170:C179
Colon (excluding rectum)	C180:C189, C260
Rectum and Rectosigmoid	C199, C209
Anus	C210:C212, C218
Liver	C220
Gallbladder	C239
Pancreas	C250:C259
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269, C488
<b>Respiratory system</b>	C30:C39
Larynx	C320:C329
Lung and bronchus	C340:C349
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383, C388, C390:C399
<b>Bones and joints</b>	C400:C419
<b>Soft tissue (including heart)</b>	C380, C470:C479, C490:C499
<b>Skin</b>	C44
Melanomas of the skin	C440:C449 (types 8720:8790)
Other skin	C440:C449
<b>Breast</b>	C500:C509
<b>Female genital system</b>	C51:C58
Cervix uteri	C530:C539
Corpus uteri	C540:C549
Uterus, NOS	C559
Ovary	C569
Other female genital system	C529, C510:C519, C570:C589
<b>Male genital system</b>	C60:C63
Prostate	C619
Testis	C620:C629

<b>Primary Site</b>	<b>Site/ Cell type</b>
Penis	C600:C609
Other male genital system	C630:C639
<b>Urinary system</b>	C64:C68
Bladder (incl. in situ)	C670:C679
Kidney and renal pelvis	C649, C659
Ureter	C669
Other urinary system	C680:C689
<b>Eye</b>	C690:C699
<b>Brain and other nervous system</b>	C70:C72
Brain	C710:C719
Other nervous system	C710:C719 (type 953)
	C700:C709
	C720:C729
<b>Endocrine</b>	C73:C75
Thyroid	C739
Other endocrine	C379, C740:C749, C750:C759
<b>Lymphomas</b>	C77
Hodgkin disease	types 9650:9667
Non-Hodgkin lymphoma	types 9590:9596, 9670:9719, 9727:9729
	type 9823, all sites except C420, C421, C424
	type 9827, all sites except C420, C421, C424
Multiple myeloma	C421, types 9731:9732, 9734
<b>Leukemias</b>	C42
Acute lymphocytic	types 9826, 9835:9837
Chronic lymphocytic	C420(type 9823), C421 (type 9823), C421 (type 9823), C424 (type 9823)
Acute myeloid	types 9840, 9861, 9866, 9867, 9871:9874, 9895:9897, 9910, 9920
Chronic myeloid	types 9863, 9875, 9876, 9945, 9946
Other	types 9733, 9742, 9800, 9801, 9805, 9820, 9831, 9832:9834, 9860, 9870, 9891, 9930, 9931, 9940, 9948, 9963, 9964
	C420 (type 9827), C421 (type 9827), C424 (type 9827)
<b>Other, ill-defined, and unknown</b>	types 9740,9741, 9750:9758, 9760:9769, 9950:9962, 9970:9989
	C760:C768, (types 8000:9589)
	C809 (types 8000:9589)
	C420:C424 (types 8000:9589)
	C770:C779 (types 8000:9589)